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Methionine at position 184 of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) was changed to valine,
isoleucine, threonine, or alanine in an HIV-1-based vector. The vectors were analyzed for replication capacity and for resistance to the
nucleoside analog 2V,3V-dideoxy-3Vthiacytidine (3TC) using a single-cycle assay. Viruses containing the valine or isoleucine mutations were
highly resistant to 3TC and replicated almost as well as the wild-type virus. The virus containing the threonine mutation was resistant to 3TC,
but replicated about 30% as well as the wild-type. The alanine mutation conferred partial resistance to 3TC, but replicated poorly. The
amounts of viral DNA synthesized decreased in 3TC-treated cells when the cells were infected with wild-type virus and the M184A mutant.
The effect of these mutations on the generation of the ends of the linear viral DNA was determined using the sequence of the 2-LTR circle
junctions. The M184T mutation increased the proportion of 2-LTR circle junctions containing a tRNA insertion, suggesting that the mutation
affected the RNase H activity of RT.
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The inhibitors currently approved for the treatment of
human immunodeficiency virus type-1 (HIV-1) infections
target viral entry and the viral enzymes protease and reverse
transcriptase (RT) (Coffin et al., 1997; Kilby et al., 1998).
RT inhibitors block the synthesis of viral DNA in infected
cells. There are two general classes of reverse transcriptase
inhibitors, nucleoside analogs (NRTIs) and nonnucleoside
inhibitors (NNRTIs). Viruses resistant to either class of drug
emerge after the initiation of drug treatment.
3TC is an NRTI; both structural and biochemical data
suggest that the mechanism of resistance to 3TC by HIV-1
RT involves steric hindrance (Gao et al., 2000; Huang et al.,
1998; Sarafianos et al., 1999). 3TC rapidly selects for RT0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: hughes@ncifcrf.gov (S.H. Hughes).variants that have either valine or isoleucine substituted for
the methionine normally found at position 184, which is the
second amino acid in the conserved YXDD motif at the
polymerase active site (Schinazi et al., 1993). Both valine
and isoleucine are h-branched amino acids. 3TC contains an
oxathiolane ring in place of the deoxyribose ring found in
dNTPs; the L or () entantiomer of 3TC is used in the
treatment of HIV-1 infections. When 3TC-TP is bound at
the active site of HIV-1 RT, the oxathiolane ring of 3TC is
closer to the amino acid at position 184 than the deoxyri-
bose ring of a normal triphosphate. If a h-branched amino
acid is present at position 184, the oxathiolane ring will
clash with the h-branch; this steric hindrance interferes with
the incorporation of 3TCTP, which leads to the high-level
drug resistance associated with M184V and M184I variants
(Gao et al., 2000; Huang et al., 1998; Sarafianos et al.,
1999).
There are data to suggest that the same mechanism for
resistance to 3TC occurs in other viral RTs. 3TC can block
the replication of FIV; the resistant viruses that are selected
have a methionine to threonine (threonine is a h-branched
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YXDD motif of the polymerase active site in FIV RT (this
position is equivalent to 184 in HIV-1 RT) (Smith et al.,
1997). However, this mutation is not usually selected in
HIV-1 RT (Schinazi et al., 2000). Treatment of hepatitis B
virus (HBV) with 3TC selects for isoleucine or valine in
place of methionine at the second position of the YXDD
motif (Tipples et al., 1996). Not all wild-type retroviruses
have a methionine at the second position of the YXDD
motif; for example, Moloney murine leukemia virus (MLV)
has valine (YVDD). The steric hindrance model predicts
that MLV should be resistant to 3TC; as predicted MLV is
relatively resistant to 3TC (Halvas et al., 2000). However, a
mutant MLV with methionine at the second position of the
YXDD motif was relatively resistant to 3TC. In vitro
experiments with purified MLV RT showed that wild-type
MLV RT was resistant to 3TCTP; an MLV RT with a
methionine at the second position of the YXDD motif was
more sensitive to 3TCTP than the wild-type enzyme with
valine at this position (Boyer et al., 2001). However, the
MLV RT with methionine in the YXDD motif was more
resistant to 3TCTP than wild-type HIV-1 RT. In addition,
substitution of alanine for methionine in the YXDD motif of
HIV-1 RT caused partial resistance to 3TCTP in vitro.
Alanine is not a h-branched amino acid and the MLV,
MLV RT, and HIV-1 RT data suggest that other factors,
for example, the exact position of the template primer in the
RT active site, may contribute to 3TC (3TCTP) resistance
(Boyer et al., 2001).
The effects of various amino acid substitutions in the
YXDD motif have been studied using both purified HIV-1
RT and in the context of the replicating virus. Several
groups have reported that the V and I mutations affect the
in vitro processivity of RT (Avidan and Hizi, 1998; Back
and Berkhout, 1997; Boyer and Hughes, 1995; Sharma and
Crumpacker, 1999). The M184V mutation has also been
reported to affect the initiation of viral DNA synthesis
(Diallo et al., 2003; Wei et al., 2003). These studies modeled
the initiation of plus- or minus-strand DNA in vitro with
RTs containing the M184V (or L74V) mutation in RT. The
mutant enzymes were deficient in the utilization of the
cognate tRNA primer or ppt in the initiation of DNA
synthesis (Diallo et al., 2003). Mutations at position 184
can also affect viral replication. Wakefield et al. (1992)
reported that there was a correlation between polymerase
activity (measured on a homopolymeric template) and viral
replication measured by the production of p24 antigen.
DNA synthesis was profoundly impaired in cells infected
with viruses containing the M184V mutation in RT that also
contain a deletion in an A-rich loop upstream of the primer
binding site (Wei et al., 2003), suggesting the M184V
mutation may impair interactions of RT with its primer-
template that are involved in the initiation of reverse
transcription. These studies describe important character-
istics of the M184 mutants; however, they do not directly
address why certain amino acid substitutions (Vand I) in theYXDD motif of HIV-1 RT are selected by 3TC, and others
(in particular A and T) are not. To understand why the Vand
I mutations are selected in HIV RT and T and A mutations
are not, we examined the effects of these mutations on viral
replication and drug sensitivity. We compared the wild-type
virus to mutants that had methionine normally present at
184 changed to valine, isoleucine, threonine, or alanine. As
expected, the M184V and M184I mutations caused high-
level resistance to 3TC and had a minimal effect on the
efficiency of replication in a single round of viral replica-
tion. The M184A and M184T viruses replicated poorly; the
M184T virus was quite resistant to 3TC, the M184A
mutation caused a slight decrease in susceptibility to 3TC.
Real-time PCR was used to monitor viral DNA synthesis in
infected cells. The results indicated that viruses containing
the M184T and M184A mutations synthesize less DNA than
the wild-type virus. In the absence of 3TC, the M184T and
M184A mutations decreased the initiation of DNA synthe-
sis. The amounts of viral DNA synthesized by the wild-type
virus and virus with the M184A mutation decreased when
cells were treated with 3TC. We also examined the effects of
these mutations on the generation of the ends of the linear
viral DNA using the 2-LTR circle junction as a surrogate for
the ends of the linear viral DNA. The M184T mutation
affected the generation of the ends of the linear viral DNA;
there was a significant increase in the number of tRNA
primer-derived sequences in circle junctions from infections
with the M184T mutant. The M184V, M184I, and M184A
mutations did not cause statistically significant increases in
the proportion of circle junctions containing sequences
derived from the tRNA primer. These results suggest that
the M184T mutation affects the level of RNase H activity.
The presence of PPT-derived sequences at the circle junc-
tions suggests that the M184T mutation could affect the
efficiency of RNase H cleavage. The effects of M184T on
RNase H activity provide additional support for the idea that
the enzymatic activities (polymerase and RNase H) of HIV-
1 RT are interdependent (Dudding and Mizrahi, 1993;
Dudding et al., 1991; Gao et al., 1998; Hughes et al.,
1998; Julias et al., 2001, 2002, 2003; Mizrahi et al., 1990,
1994).Results
Vectors and replication assay
The vector pNLNgoMIVR-E-.LUC is based largely on
the NL4-3 isolate of HIV-1 (see Fig. 1 and Materials and
methods for information on the construction of the vector).
The vector expresses gag and pol, but the envelope gene has
been inactivated. The luciferase gene has been introduced
into the nef open reading frame. Mutations in the YXDD
motif of RT were introduced into the vector as SmaI to
Asp718 fragments from plasmids that express recombinant
HIV-1 RT in Escherichia coli (Boyer et al., 1992). Viral
Fig. 1. The HIV-1-based vector used to measure viral infectivity. The
HIV-1 vector pNLNgoMIVRE.LUC was created from the vector
pNLNgoMIV.RE.HSA as described in Materials and methods. The vector
expresses the firefly luciferase gene from the nef open reading frame. The
env gene and the vpr gene have been inactivated in this vector. The vector is
packaged into virions using the VSV-g envelope glycoproteins (Bartz and
Vodicka, 1997; Yee et al., 1994). The drawing is not to scale. The vector
undergoes only a single cycle of replication.
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nine, and threonine in place of the methionine normally
found at position 184 of RT. The vector was packaged into
virions by co-transfecting 293 cells with the plasmid con-
taining the vector and with pHCMV-g, a plasmid that
expresses the VSV-g envelope (see Materials and methods).
3TC resistance
Virions containing wild-type RT, and RTs with the
valine, isoleucine, threonine, and alanine substitutions at
position 184 were generated and used to infect HOS cells.
The effects of 3TC on the replication of the viruses were
determined by treating cells with 0, 5, 10, and 20 AM 3TC
(Fig. 2). Data from a representative experiment are shown.
The relative titers and drug resistance profiles were highly
reproducible between experiments (variation of about F5%
or less after normalization). As expected, the wild-type virus
was sensitive to 3TC; 5 AM of 3TC reduced virus replica-
tion by approximately 90%. The RT mutants containing
valine and isoleucine at position 184 had virus titers
approximately 90% of the wild-type titer in the untreated
sample; as expected, these mutants displayed high-level
resistance to 3TC and were not measurably inhibited byFig. 2. The relative infectivity of the virus and drug resistance of viruses
containing mutations at position 184 in RT. The relative infectivity is shown
on the y-axis, the concentration of 3TC is shown on the x-axis.20 AM 3TC. In the absence of 3TC, the mutant containing
threonine at position 184 had a titer of about 30% of the
wild-type virus. Threonine containing the mutant also dis-
played high-level resistance to 3TC. The mutant containing
alanine at 184 had the lowest relative titer, approximately
15% the titer of wild type. The alanine mutation caused
modest resistance to 3TC; 5 AM inhibited the wild-type
virus by 90%, but M184A was inhibited by approximately
50%.
Synthesis of viral DNA in cells infected with WT virus and
viruses containing the M184T and M184A mutations in the
presence and absence of 3TC
The effects of mutations at position 184 on viral DNA
synthesis were determined by infecting HOS cells with
wild-type virus and viruses containing the M184T or
M184A mutations. Total DNA was isolated from cells 24
h after infection. Viral DNA synthesis in infected cells was
monitored using quantitative real-time PCR (see Fig. 3).
The DNA copy number is shown on the y-axis and the RT
mutant is shown on the x-axis. Virions were generated that
contained wild-type RT and the M184T, M184A, and the
D110E (polymerase active site) mutants. The D110E muta-
tion abolishes polymerase activity; consequently, viruses
containing this mutation cannot synthesize viral DNA. This
mutant was included as a control to monitor residual DNA
carryover from the transfection process used to generate the
virions. The DNA copy number for the D110E sample was
approximately 100 copies for RU5, U3, or Gag. These data
indicate that there is minimal plasmid carryover from theFig. 3. Determination of viral DNA copy number in infected cells. The x-
axis designates the virus and indicates the presence or absence of 3TC
treatment. The y-axis shows the DNA copy number on a logarithmic scale.
Taqman probe and primer and primer sets were used in quantitative PCR
reactions to determine the viral DNA copy number in infected cells (see
Materials and methods). Quantitative PCR was used to measure RU5 (black
bars) to measure initiation of DNA synthesis, U3 (checkered bars to
measure first strand transfer), Gag (white bars) to measure elongation, and
2-LTR circles (diagonally striped bars) were measured as a surrogate for the
completion of viral DNA synthesis.
J.G. Julias et al. / Virology 322 (2004) 13–2116transfection process. There were no 2-LTR circle junctions
detected in samples derived from cells infected with virions
containing the D110E mutation. The plasmid used to
generate the virus stock does not contain a 2-LTR circle
junction; retroviral reverse transcription is required to gen-
erate the linear viral DNA that is joined to form the 2-LTR
circles.
The viral DNA copy numbers in cells infected with the
wild-type virus were approximately 4  106 for RU5 and
U3 (Fig. 3). About 40% of DNAs undergoing first strand
transfer was elongated through the gag gene. There were 7
 103 copies of the 2-LTR circle junction present in the
sample. When the cells infected with the wild-type virus
were treated with 20 AM 3TC, no effect was seen on the
amounts of DNA synthesized from RU5 or U3; however,
there was a 10-fold decrease in the amount of gag DNA.
3TC treatment caused an approximately 30-fold reduction in
the number of 2-LTR circles. These results are consistent
with the decrease in virus titer observed when 20 AM of
3TC was added to cells infected with the wild-type virus.
When cells were infected with viruses containing the
M184T mutation, there were approximately 1  106 copies
of DNA for RU5 and U3, indicating a decrease in the
initiation of DNA synthesis (Fig. 3). There were 3  105
copies of gag DNA indicating that the M184T mutant and
wild-type RTs carry out minus-strand elongation with equal
efficiency. There were 1.7  103 copies of the 2-LTR circle
junction measured. The viral DNA copy numbers were
similar to samples treated with 20 AM 3TC and the samples
that did not receive 3TC, consistent with the observationFig. 4. The sequence of the 2-LTR circle junction. The sequence of 2-LTR circl
virions with reduced levels of RNase H, and from cells infected with vectors contai
fraction of 2-LTR circle junctions containing the given property (1.00 = 100%, 0.60
H activity are from previously published experiments (Julias et al., 2003).that viruses containing the M184T mutation are highly
resistant to 3TC.
The M184A mutation caused a decrease in the amount of
viral DNA synthesized. There were 5.2  105 copies of
RU5, indicating a decrease at the level of initiation of DNA
synthesis. There were 2.3  105 copies of U3, 2.0  105
copies of gag, and 2  102 copies of 2-LTR circles. When
the cells were treated with 20 AM 3TC, a 10-fold decrease in
the amount of gag DNAwas observed. There was also a 10-
fold decrease in the amount of 2-LTR circle junctions. These
results are consistent with the partial resistance to 3TC
conferred by the M184A mutation.
M184T affects RNase H cleavage
The removal of tRNA and PPT primers by RNase H
defines the ends of linear viral DNA. The removal of the
tRNA defines the right end; the removal of the PPT defines
the left end. A portion of the linear viral DNAs is ligated, by
host cell ligases, to form 2-LTR circles (Li et al., 2001). To
determine if mutations at position 184 in RT alter the
efficiency or specificity of RNase H, we used the sequence
of the 2-LTR circle junction as a surrogate for the ends of
the genome (Fig. 4). 2-LTR circle junctions were amplified
from cells infected with viruses containing wild-type RT,
with viruses containing reduced RNase H activity (viruses
generated by co-transfecting 293 cells with a mixture in
which 10% of the plasmids encoded wild-type RT and 90%
of the plasmids encoded RT with the active site mutation
E478Q in RNase H), and with viruses with mutations ate junctions was determined from cells infected with wild-type virus, from
ning mutations at position 184 in RT. The numbers in the table represent the
= 60%, etc.). The data for the wild-type RT and virions with reduced RNase
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LTR circle junction was determined by sequencing approx-
imately 100 2-LTR circle junction clones from infections
with the wild-type virus, the virus with reduced RNase H
activity, and each of the 184 mutants. A summary of the
sequence analysis is shown (Fig. 4). When the sequence of
the 2-LTR circle junction is correct (the complete sequence
from the ends of the linear viral DNA is present), this is
defined as a consensus 2-LTR circle junction. The propor-
tion of 2-LTR circle junctions having a consensus sequence
is shown in the top row of Fig. 4. We previously generated
two independent sets of data after infecting cells with wild-
type virus and virions with reduced RNase H activity. The
fraction of consensus 2-LTR circle junction sequences was
0.60 from infections with viruses containing wild-type RT in
both experiments and 0.54 and 0.48 with virions containing
reduced RNase H activity (Julias et al., 2003). The fraction
of consensus junctions was 0.58, 0.51, 0.69, and 0.46 for the
viruses containing the M184V, M184I, M184A, and M184T
mutations, respectively.
When cells were infected with the wild-type virus, the
fraction of 2-LTR circles that contained tRNA insertions was
0.01. Some mutations at 184 caused a small increase in the
fraction of circle junctions containing tRNA insertions. The
fraction containing tRNAs was 0.06, 0.05, and 0.03 for the
M184 V, I, and A mutants, respectively. This is not statisti-
cally different than wild type. However, the 2-LTR circle
junctions derived from infecting cells with the M184T
mutant had a larger increase in the fraction of circle junctions
containing tRNA; the fraction was 0.14. This is statistically
significant (P < 0.05) and suggests that a threonine at
position 184 caused a decrease in RNase H activity.
If the PPT is properly generated, but is not removed (or is
incompletely removed) by RNase H, then a 2-LTR circle
junction containing a simple PPT insertion is generated.
Simple PPT insertions can also be generated if an improper
primer is used to initiate plus-strand DNA synthesis. Two
independent sets of data were analyzed after infecting HOS
cells with wild-type virus and virions with reduced RNase H
activity; the frequency of simple PPT insertions was 0.01
and 0.02 for wild-type and 0.01 in both experiments with
virions with reduced RNase H activity (Fig. 4). The 2-LTR
circle junctions derived from infecting cells with the 184A
mutant contained simple PPT insertions at a fraction of 0.01;
the same fraction of simple PPT inserts as the circle
junctions derived from infection with wild-type virus or
virions with reduced RNase H activity. The presence of Vor
I at position 184 increased the fraction of circle junctions
containing PPT inserts to 0.04 and 0.05 (for 184 V and I,
respectively). These increases are not statistically signifi-
cant. However, the increase in the proportion of 2-LTR
circle junctions containing a PPT seen after infecting cells
with the 184T virus (0.08) is statistically significant (P <
0.05). The fact that there is no increase in PPT insertions
when the RNase H activity is reduced by 90% suggests that
the increase in PPT insertions seen with the M184T mutantsis caused by a change in RNase H specificity, and not
simply by a decrease in RNase H activity.
2-LTR circle junctions containing PPTs with short flank-
ing sequences could arise by improper generation of PPT. If
the aberrant PPT is then retained because RNase H fails to
remove the aberrant primer, a PPT plus a short flank (the U-
tract) will be found at the 2-LTR circle junction. This type of
insertion can also arise from plus-strand priming upstream
of the normal site of initiation. PPTs with short flanking
sequences were not observed in 2-LTR circle junctions
derived by infecting cells with virions containing wild-type
RT or virions with reduced RNase H activity. Aberrant 2-
LTR circle junctions containing short flanking sequences
were observed at low frequency (0.01) after infecting cells
with viruses containing the M184T mutation in RT; this is
not statistically significant.
A PPTwith a long flanking sequence can arise if RT uses
(and removes) a primer upstream of the PPT to initiate plus-
strand DNA synthesis, or if an aberrant primer is used, but
not removed. The resulting 2-LTR circle junction contains
the PPT with a considerable amount of flanking sequence
(typically >20 nt upstream of the PPT). This type of aberrant
2-LTR circle junction was observed at a frequency of 0.02
when RNase H activity was reduced in the virions. Insertions
of this type were also observed at approximately the same
frequency in the circle junctions derived from infections with
the M184I, A, and T mutants. The frequency of PPTs with
long flanks was 0.01, 0.01, and 0.02, respectively.
If RNase H fails to correctly recognize the 3Vend of the
PPT and cleaves within U3 to generate the 3Vend of the RNA
primer, then the PPT primer is removed, there will be a
small deletion in the 5V end of U3. We analyzed the
frequency of small deletions in U3 or U5 to determine if
the 184 mutants incorrectly generate (and remove) the U3
primer. We previously showed that the RNase H primer grip
mutants caused a dramatic increase in the frequency of 5-bp
deletions in the U3 region (Julias et al., 2002); however, no
similar increase in short deletions in U3 was observed with
the M184V, M184I, M184A, or M184T mutants (data not
shown).Discussion
Treatment of HIV-1 with 3TC results in the emergence of
M184I and M184V mutations in RT (Schinazi et al., 1993).
These amino acid changes at the polymerase active site
substitute a h-branched amino acid for methionine. During a
single-cycle assay, the replication capacity of these variants
was about 90% of wild type, and high-level resistance to
3TC was observed. Because this assay is limited to a single
cycle of retroviral replication, we would not expect to see a
dramatic effect on viral replication. If viruses containing
these mutations were allowed to undergo several rounds of
replication and the viruses had a replication capacity of 90%
of the wild-type virus in each cycle of replication, a larger
J.G. Julias et al. / Virology 322 (2004) 13–2118effect would be seen. Although it is less sensitive to small
changes in replication capacity, a single-cycle assay has the
advantage that the exact number of replication cycles is
known and reversion of the mutations is not a concern. The
M184T mutation also replaces methionine with a h-
branched amino acid; as expected, the virus is highly
resistant to 3TC. However, the virus has a decreased
replication capacity; the relative titer is about 30% of wild
type. M184A replicates poorly and confers only minimal
resistance to 3TC.
The analysis of viral DNA synthesis in cells infected with
wild-type virus and viruses containing the M184T and
M184A mutations was consistent with the results of the
effects of these mutations on virus titer. Both mutations
caused a decrease in the initiation of DNA synthesis. In
contrast to valine and isoleucine, the h-branch of threonine
contains a hydroxyl group (OH). The initiation of DNA
synthesis is a difficult step for HIV-1 RT both in vitro and in
vivo (Isel et al., 1996; Julias et al., 2002; Launchy et al.,
2000). One possible explanation is that it is difficult for the
enzyme to bend the RNA–RNA substrate used to initiate
DNA synthesis to conform to the structures seen with
RNA–DNA and DNA–DNA substrates. This would make
the initiation step particularly vulnerable to changes that
affect the binding of the nucleic acid or the regions around
the polymerase and RNase H active sites. It is also possible
that it is the presence of the hydroxyl group on the side
chain of threonine that makes it more difficult for RT to
appropriately extend an RNA–RNA duplex during the
initiation of reverse transcription. The OH group may affect
the positioning of the dNTP substrate or the template primer.
The h-branched amino acids V and I narrow the sugar-
binding pocket of HIV-1 RT, which blocks the incorporation
of 3TCTP and reduces the incorporation of other nucleo-
sides with L-sugars (Gao et al., 2000; Huang et al., 1998;
Sarafianos et al., 1999). However, V and I affect the
incorporation of normal dNTPs to a minimal extent. It is
possible that the presence of the OH of threonine narrows
the sugar pocket enough to interfere with the incorporation
of normal dNTPs. However, there is no inherent problem
with a threonine at this position in the active site of an RT:
3TC-resistant FIV has a T in the second position of the
YXDD motif. Although alanine does not have a h-branch,
the presence of alanine at position 184 affects polymeriza-
tion and gives rise to low-level resistance to 3TC. 184 is
close to both the sugar ring of the incoming dNTP and the
template primer. An alanine at position 184 could affect the
incorporation of dNTPs and 3TCTP either directly or by
repositioning the template primer (Boyer and Hughes,
1995).
When M184V, M184I, and M184A mutants were ana-
lyzed in vitro, processivity defects were observed for the
mutant RTs (Back et al., 1996; Back et al., 1997; Boyer and
Hughes, 1995; Wei et al., 2003; Sharma and Crumpacker,
1999). The data we obtained with a one-round vector do not
reveal any obvious elongation defects for these mutantsduring viral replication. Previously, when we made pheno-
typically mixed virions with reduced levels of polymerase
activity, we saw defects at the level of the initiation of DNA
synthesis and in some aspects of plus-strand DNA synthesis
(Julias et al., 2001). Elongation was not measurably affected
by limiting the amount of polymerase in the virion. It is
possible that we did not observe elongation defects when the
M184 mutations were tested using a one-round vector
replicating in cultured cells because the cells were growing
rapidly and presumably have relatively high levels of
dNTPs. When HIV-1 infects primary cells, where the levels
of dNTPs are lower, elongation defects are more pro-
nounced and the rate of viral DNA synthesis is affected
(Back et al., 1997).
There are reports that mutations at 184 affect virus
replication (Miller et al., 1999; Newstein and Desrosiers,
2001). When E89G and M184V mutations were introduced
into the RT of SIVmac, there was extensive reversion of the
mutation at E89, but the M184V mutation persisted (News-
tein and Desrosiers, 2001). The authors suggest that rever-
sion of M184V to wild type was not observed because two
nucleotide substitutions are needed for the reversion. The
persistence of the M184V mutation in virus replicating in
the absence of 3TC suggests that viruses carrying this
mutation replicate relatively well, however the P272S mu-
tation was present in a high proportion of the samples. It is
possible that this mutation affected the replication capacity
of the M184V virus. HIV-1 containing the M184V mutation
has a decreased replication capacity in PBMCs (Miller et al.,
1999); similarly, SIV with mutations at 184 shows reduced
replication capacity (Van Rompay et al., 2002).
The emergence of M184I and M184V viruses during
3TC treatment is rapid, and the viruses are highly resistant
to 3TC; however, the M184T virus, which is also 3TC
resistant, is seen only rarely (Cho et al., 2002). Because the
M184T virus is highly resistant to 3TC, the relatively low
replication capacity of the M184T virus accounts for its
rarity in patients. The M184A virus has a greatly reduced
replication capacity and is only marginally resistant to 3TC;
consequently, this virus has not been found in patients.
The observation that the M184T mutation, which is in
the polymerase active site, not only affects DNA synthesis
and drug resistance, but also RNase H cleavage, suggests
that M184T affects the positioning of the nucleic acid during
viral replication. The fact that M184T affects RNase H
cleavage provides support for the idea that the M184T
mutation affects DNA synthesis because it alters the posi-
tioning of the nucleic acid.
The enzymatic activities of HIV-1 RT (polymerase and
RNase H) are interdependent. The isolated RNase H domain
of HIV-1 RT has little enzymatic activity because the RNase
H domain, when expressed separately from the polymerase
domain, binds nucleic acid substrates poorly. The addition of
part of the polymerase domain (the connection subdomain)
restores RNase H activity (Smith et al., 1994). This indicates
that the polymerase domain helps RNase H properly bind its
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RNase H domain of HIV-1 can affect the initiation of DNA
synthesis and mutations in the RNase H domain of MLVand
HIV can decrease the fidelity of DNA synthesis during
reverse transcription (Zhang et al., 2002). Because the active
sites of polymerase and RNase H are separated by 17–18
nucleotides, the simple explanation is that amino acids in
both domains play important roles in binding and position-
ing the nucleic acid relative to both of the active sites of RT.
The proper positioning of the nucleic acid is critical for the
precise RNase H cleavages that are needed to generate linear
viral DNAs with correct ends. Analysis of the 2-LTR circle
junctions from cells infected with mutants at position 184 in
HIV-1 RT demonstrated that the M184T mutation affects the
RNase H cleavages that generate the ends of the linear viral
DNA during reverse transcription. This result indicates that
polymerase active site mutations can affect RNase H activ-
ity; this strongly supports the notion that the two enzymatic
activities of RT are interdependent.Materials and methods
Vector construction
The construction of the parental vector pNLNgo-
MIVRE.HSA has been described previously (Julias,
2001). Briefly, this vector expresses the HIV-1 gag-pol
gene, but the env gene is inactivated in the vector. Unique
restriction endonuclease cleavage sites for SmaI and Asp718
are present in the pol coding region to facilitate the cloning
of mutant RTs from previously described HIV-1 RT expres-
sion plasmids (Boyer et al., 1992). The murine heat stable
antigen gene (CD24 or hsa) is expressed from the nef
reading frame in this vector (Wegner et al., 1993). The
hsa gene is flanked by XhoI and NotI restriction endonu-
clease cleavage sites. These sites were used to introduced
the luciferase gene to generate pNLNgoMIVR-E-.LUC
series of vectors.
Cells, transfection, and infection
The human embryonal kidney cell line 293 was obtained
from American Type Culture Collection (ATCC). The
human osteosarcoma cell line HOS was obtained from Dr.
Richard Schwartz (Michigan State University, Lansing,
MI). HOS and 293 cells were maintained in Dulbecco’s
modified Eagle’s medium (Life Technologies) supplemented
with 5% fetal bovine serum, 5% newborn calf serum, and
penicillin (50 units/ml) plus streptomycin (50 Ag/ml) (Quality
Biological).
Transfection, infection, and luciferase protocol
293 cells were transfected with 2 Ag of pNLNgo-
MIVRE.LUC DNA containing different mutations atposition 184 in RT and 2 Ag of pHCMV-g (obtained from
Dr. Jane Burns, UCSD) using the calcium phosphate meth-
od. 293 cells were plated in 100-mm diameter dishes at a
density of 1.8  106 cells per plate on the day before
transfection; at this density, the cells are approximately 30%
confluent on the day of transfection. The precipitate was
added to 293 cells dropwise. Eight hours after transfection,
the cells were washed once with 8 ml of Dulbecco’s
phosphate-buffered saline (PBS) (Gibco BRL/Life Technol-
ogies) and fresh medium was added. The medium was
changed again 24 h after transfection. The 48-h supernatants
were harvested, clarified by low-speed centrifugation, fil-
tered through a Millex-GS 0.22-Am filter (Millipore), and
used to infect HOS cells. The amount of p24 in the samples
was determined using the HIV-1 p24 antigen capture assay
kit (AIDS Vaccine Program, SAIC; Frederick, MD); this
information was used to control for the amount of virus in
the samples. The effects of 3TC (Moravek Biochemical)
were determined by pretreating cells with 3TC for 4 h before
the infection. The virus was allowed to adsorb to the cells
for 2 h, then fresh medium (with 3TC) was added. Forty-
eight hours after infection, the cells were washed once with
2 ml PBS, and then lysed using 0.5 ml of Glo-Lysis Buffer
(Promega). The luciferase activity was determined using the
Steady-Glo reagent system (Promega). The luciferase activ-
ity was normalized to the amounts of p24 antigen present in
the supernatants and to the protein concentration of the
lysate.
Transfections, infections, and nucleic acid extractions for
2-LTR circle junction analysis
293 cells were transfected with 5 Ag of wild-type
pNLNgoMIVRE.HSA vector DNA or with DNA for
vectors encoding amino acid substitutions V, I, T, or A at
position 184 in RT and 3 Ag of pHCMV using the calcium
phosphate method. The 48-h supernatants were harvested,
clarified by centrifugation, and filtered. Two microliters of
virus-containing supernatant was used to infect HOS cells
plated at a density of 1  106 cells per 100-mm diameter
plate the day before infection. The supernatants were left on
the cells for 4 h and fresh medium was added. Total DNA
was isolated from HOS cells approximately 24 h after
infection using the viral blood DNA kit (Qiagen).
PCR amplification, cloning, and sequencing of 2-LTR circle
junctions
The 2-LTR circle junctions were amplified in 100-
Al reactions using an upstream PCR primer that anneals to
the RU5 junction and a downstream primer that anneals to
the U3 region of the LTR as previously described (Julias et
al., 2002). The expected product is approximately 350 bp
long and is flanked by EcoRI and XbaI sites that were
introduced by the PCR primers. The PCR product was
digested with EcoRI and XbaI and cloned into the cloning
J.G. Julias et al. / Virology 322 (2004) 13–2120plasmid SK (Stratagene). The 2-LTR circle junction clones
were analyzed using restriction endonuclease digestion and
DNA sequence analysis.
Determination of viral DNA copy number using real-time
PCR
HOS cells receiving 3TC treatment were incubated with
20 AM 3TC (final concentration) for 16 h before infection
and 24 h following infection. Transfections used to generate
the virus, infections, and DNA isolation were performed as
previously described (Julias et al., 2001). Quantitative real-
time PCR used to determine viral DNA copy number was
performed with the ABI 7700, 2 Universal Master Mix,
and Taqman probe DNA primer sets as previously described
(Julias et al., 2001).Acknowledgments
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